Aaron S Farberg1,2,3,4,5, Richard R Winkelmann1,2,3,4,5, Natalie Tucker1,2,3,4,5, Richard White1,2,3,4,5, Darrell S Rigel1,2,3,4,5. 1. Dr. Farberg is with the Icahn School of Medicine, Dermatology, at Mount Sinai in New York, New York. 2. Dr. Winkelmann is with Ohio Health, Dermatology, Columbus, Ohio. 3. Ms. Tucker is with STRATA Skin Sciences Inc. in Horsham, Pennsylvania. 4. Mr. White is with Iris Interactive System in Cody, Wyoming. 5. Dr. Rigel is with the New York University School of Medicine, Dermatology, in New York, New York.
Abstract
BACKGROUND: Early diagnosis of melanoma is critical to survival. New technologies, such as a multi-spectral digital skin lesion analysis (MSDSLA) device [MelaFind, STRATA Skin Sciences, Horsham, Pennsylvania] may be useful to enhance clinician evaluation of concerning pigmented skin lesions. Previous studies evaluated the effect of only the binary output. OBJECTIVE: The objective of this study was to determine how decisions dermatologists make regarding pigmented lesion biopsies are impacted by providing both the underlying classifier score (CS) and associated probability risk provided by multi-spectral digital skin lesion analysis. This outcome was also compared against the improvement reported with the provision of only the binary output. METHODS: Dermatologists attending an educational conference evaluated 50 pigmented lesions (25 melanomas and 25 benign lesions). Participants were asked if they would biopsy the lesion based on clinical images, and were asked this question again after being shown multi-spectral digital skin lesion analysis data that included the probability graphs and classifier score. RESULTS: Data were analyzed from a total of 160 United States board-certified dermatologists. Biopsy sensitivity for melanoma improved from 76 percent following clinical evaluation to 92 percent after quantitative multi-spectral digital skin lesion analysis information was provided (p<0.0001). Specificity improved from 52 percent to 79 percent (p<0.0001). The positive predictive value increased from 61 percent to 81 percent (p<0.01) when the quantitative data were provided. Negative predictive value also increased (68% vs. 91%, p<0.01), and overall biopsy accuracy was greater with multi-spectral digital skin lesion analysis (64% vs. 86%, p<0.001). Interrater reliability improved (intraclass correlation 0.466 before, 0.559 after). CONCLUSION: Incorporating the classifier score and probability data into physician evaluation of pigmented lesions led to both increased sensitivity and specificity, thereby resulting in more accurate biopsy decisions.
BACKGROUND: Early diagnosis of melanoma is critical to survival. New technologies, such as a multi-spectral digital skin lesion analysis (MSDSLA) device [MelaFind, STRATA Skin Sciences, Horsham, Pennsylvania] may be useful to enhance clinician evaluation of concerning pigmented skin lesions. Previous studies evaluated the effect of only the binary output. OBJECTIVE: The objective of this study was to determine how decisions dermatologists make regarding pigmented lesion biopsies are impacted by providing both the underlying classifier score (CS) and associated probability risk provided by multi-spectral digital skin lesion analysis. This outcome was also compared against the improvement reported with the provision of only the binary output. METHODS: Dermatologists attending an educational conference evaluated 50 pigmented lesions (25 melanomas and 25 benign lesions). Participants were asked if they would biopsy the lesion based on clinical images, and were asked this question again after being shown multi-spectral digital skin lesion analysis data that included the probability graphs and classifier score. RESULTS: Data were analyzed from a total of 160 United States board-certified dermatologists. Biopsy sensitivity for melanoma improved from 76 percent following clinical evaluation to 92 percent after quantitative multi-spectral digital skin lesion analysis information was provided (p<0.0001). Specificity improved from 52 percent to 79 percent (p<0.0001). The positive predictive value increased from 61 percent to 81 percent (p<0.01) when the quantitative data were provided. Negative predictive value also increased (68% vs. 91%, p<0.01), and overall biopsy accuracy was greater with multi-spectral digital skin lesion analysis (64% vs. 86%, p<0.001). Interrater reliability improved (intraclass correlation 0.466 before, 0.559 after). CONCLUSION: Incorporating the classifier score and probability data into physician evaluation of pigmented lesions led to both increased sensitivity and specificity, thereby resulting in more accurate biopsy decisions.
Authors: Richard R Winkelmann; Darrell S Rigel; Emily Kollmann; Nicole Swenson; Natalie Tucker; Mark S Nestor Journal: J Clin Aesthet Dermatol Date: 2015-03
Authors: Gary Monheit; Armand B Cognetta; Laura Ferris; Harold Rabinovitz; Kenneth Gross; Mary Martini; James M Grichnik; Martin Mihm; Victor G Prieto; Paul Googe; Roy King; Alicia Toledano; Nikolai Kabelev; Maciej Wojton; Dina Gutkowicz-Krusin Journal: Arch Dermatol Date: 2010-10-18
Authors: M Elbaum; A W Kopf; H S Rabinovitz; R G Langley; H Kamino; M C Mihm; A J Sober; G L Peck; A Bogdan; D Gutkowicz-Krusin; M Greenebaum; S Keem; M Oliviero; S Wang Journal: J Am Acad Dermatol Date: 2001-02 Impact factor: 11.527
Authors: Arturo Pardo; José A Gutiérrez-Gutiérrez; I Lihacova; José M López-Higuera; Olga M Conde Journal: Biomed Opt Express Date: 2018-11-15 Impact factor: 3.732
Authors: Anna-Marie Hosking; Brandon J Coakley; Dorothy Chang; Faezeh Talebi-Liasi; Samantha Lish; Sung Won Lee; Amanda M Zong; Ian Moore; James Browning; Steven L Jacques; James G Krueger; Kristen M Kelly; Kenneth G Linden; Daniel S Gareau Journal: Lasers Surg Med Date: 2019-01-17 Impact factor: 4.025